Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) ...
Tags: Can-Fite BioPharma, OphthaliX, placebo-controlled phase III study
Duke University’s Duke Clinical Research Institute (DCRI) has been selected by Oxygen Biotherapeutics, a pharmaceutical company, to conduct the Phase III clinical trial of the company’s newly acquired compound, levosimendan. ...
GlaxoSmithKline (GSK) has received FDA approval for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The approval is based on the results of the randomized, ...
Tags: advanced soft tissue sarcoma, STS, soft tissue sarcomas, GlaxoSmithKline